Declining Antibody Affinity Over Time After Human Vaccination With a Plasmodium falciparum Merozoite Vaccine Candidate

J Infect Dis. 2024 Sep 23;230(3):e753-e757. doi: 10.1093/infdis/jiae259.

Abstract

Maintaining high-affinity antibodies after vaccination may be important for long-lasting immunity to malaria, but data on induction and kinetics of affinity is lacking. In a phase 1 malaria vaccine trial, antibody affinity increased following a second vaccination but declined substantially over 12 months, suggesting poor maintenance of high-affinity antibodies.

Clinical trials registration: Australian New Zealand Clinical Trials Registry ACTRN12607000552482.

Keywords: affinity maintenance; antibody; antibody affinity; malaria; malaria vaccine.

Publication types

  • Clinical Trial, Phase I
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Protozoan* / immunology
  • Antibody Affinity*
  • Australia
  • Female
  • Humans
  • Malaria Vaccines* / administration & dosage
  • Malaria Vaccines* / immunology
  • Malaria, Falciparum* / immunology
  • Malaria, Falciparum* / prevention & control
  • Male
  • Merozoites / immunology
  • Plasmodium falciparum* / immunology
  • Vaccination
  • Young Adult

Substances

  • Malaria Vaccines
  • Antibodies, Protozoan